QC
CBIO

Quadrature Capital’s Crescent Biopharma CBIO Stock Holding History

Quadrature Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$384K Buy
20,917
+7,671
+58% +$88.1K ﹤0.01% 884
2025
Q4 		$157K Buy
+13,246
New +$169K ﹤0.01% 1019

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quadrature Capital's CBIO Position: Q1 2026 in Review

Quadrature Capital increased its Crescent Biopharma (CBIO) stake by 58% in Q1 2026, buying an estimated $88.1K and bringing the position to 20,917 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Quadrature Capital first reported a position in CBIO in Q4 2025 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Quadrature Capital held 20,917 shares of Crescent Biopharma worth $384K as of Q1 2026.
  • Quadrature Capital bought 7,671 Crescent Biopharma shares in Q1 2026, an estimated $88.1K.
  • Crescent Biopharma made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #884 holding.
  • Quadrature Capital first reported a position in Crescent Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.